MORE VIDEOS
Explore more

Latest videos

Imaging in ATTR Cardiac Amyloidosis: How it is used for Diagnosis and Treatment Response
Imaging in ATTR Cardiac Amyloidosis: How it is used for Diagnosis and Treatment Response administrator 1 Views • 1 month ago

Frederick L. Ruberg, MD
Associate Chief for Cardiovascular Medicine
Boston University Medical Center
Professor of Medicine
Boston University School of Medicine, Boston, MA

Presented at the 2023 Amyloidosis Support Groups ATTR/Hereditary Meeting, Saturday, October 28, 2023
What is cardiac amyloidosis?
What is cardiac amyloidosis? administrator 0 Views • 1 month ago

Upstate's new chair of the department of medicine is a cardiologist who has a special interest in cardiac amyloidosis, a condition that can lead to heart failure but could be treatable if diagnosed early. Cynthia Taub, MD, explains the condition, how it develops and how it can be diagnosed. She also goes over treatments and the outlook in this "The Informed Patient" episode.

“The Informed Patient” is a podcast that covers health, science and medicine, featuring experts from Central New York’s only academic medical center. Upstate Medical University has four colleges (Medicine, Nursing, Health Professions and Graduate Studies); a robust research enterprise; and an extensive clinical health care system that extends way beyond Syracuse.

For more information, please visit: https://www.upstate.edu/informed/

Cardiac Amyloidosis Part 1: Understanding Types and Risks Video - Brigham and Women's Hospital
Cardiac Amyloidosis Part 1: Understanding Types and Risks Video - Brigham and Women's Hospital administrator 0 Views • 1 month ago

In this video, Rodney H. Falk, MD, discusses the evolution and expanded scope of the Cardiac Amyloidosis Program at Brigham and Women’s Hospital, as well as the different types and risk factors for developing amyloidosis.

Cardiac Amyloidosis Video Part 2 - Advancing Diagnosis and Treatment: https://youtu.be/c3SKQkL-Jd0

Learn More:
https://www.brighamandwomens.o....rg/heart-and-vascula

Cardiac Amyloidosis: Evaluating Patients with Suspected Cardiac Amyloidosis
Cardiac Amyloidosis: Evaluating Patients with Suspected Cardiac Amyloidosis administrator 0 Views • 1 month ago

SNMMI has produced a series of educational vignettes on more accurately diagnosing and managing Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

These short video vignettes will educate the nuclear medicine and medical community on the necessary background and practical skills for acquisition and interpretation of nuclear scans for diagnosis of ATTR-CM.

Learn more at www.snmmi.org/ATTR-CM

Funded by a grant from Pfizer.

The main goals of therapy in AL amyloidosis
The main goals of therapy in AL amyloidosis administrator 0 Views • 1 month ago

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses the primary goals of therapy in light chain (AL) amyloidosis. The main objective is to improve survival by achieving a profound hematologic response. Complete response (CR) and very good partial response (VGPR) are key targets, as they are associated with better survival outcomes. The role of anti-amyloid agents is still under investigation, with ongoing studies expected to provide further insights. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
What is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)?
What is Transthyretin Amyloid Cardiomyopathy (ATTR-CM)? administrator 0 Views • 1 month ago

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rarely diagnosed fatal heart disease affecting an estimated 400,000 people globally, although the true prevalence is unknown and may be higher. Bayer is committed to optimize the care for patients living with this progressive disease, to prolong lives, and improve patients’ quality of life.
What you need to know about Multiple Myeloma & Amyloidosis
What you need to know about Multiple Myeloma & Amyloidosis administrator 1 Views • 1 month ago

In this episode of The Doc Is In, we delve into the intricacies of Multiple Myeloma and Amyloidosis with Wesam Ahmed, MD, PhD, Department Chair, Medical Oncology & Hematology, Oncology Institute. We explore the two closely related, yet distinct hematologic disorders and discuss all aspects of the diseases from diagnosis through treatment.

Moderated by Derrick Keddington
Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024
Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024 administrator 1 Views • 1 month ago

Dr Hans Lee gives an update on therapies for newly diagnosed AL amyloidosis patients.

Link to ASH playlist: https://healthtree.org/blood-c....ancer/university/mod

ASH Abstract: Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
#ASH24 #Myeloma #mmsm

Follow HealthTree: https://linktr.ee/HealthTreeUniversity

Cardiac Amyloidosis Treatment and Care with Dr. Jan Griffin
Cardiac Amyloidosis Treatment and Care with Dr. Jan Griffin administrator 0 Views • 1 month ago

The MUSC Health Amyloidosis Center of Excellence (https://muschealth.org/medical....-services/heart/card offers a multidisciplinary approach to cardiac amyloidosis, with expertise from specialists such as Dr. Jan Griffin (https://providers.muschealth.o....rg/sc/charleston/jan . Treatments have greatly advanced in recent years for this rare and life-threatening condition. In this episode, Dr. Griffin discusses these advancements and therapies available to treat this condition as well as ongoing research on this condition.

Identifying early signs of amyloidosis: increasing awareness, education & improving diagnoses
Identifying early signs of amyloidosis: increasing awareness, education & improving diagnoses administrator 1 Views • 1 month ago

Joselle Cook, MBBS, Mayo Clinic, Rochester, MN, comments on the value of identifying early signs and symptoms of systemic light chain (AL) amyloidosis, a condition associated with significant morbidity and mortality. Dr Cook highlights the need for clinicians to be aware of the vague but distinct patterns of fatigue, weight loss, and cardiac symptoms, which can trigger suspicion of systemic amyloidosis. She proposes the development of better infographics and educational material, as well as the integration of AI-powered symptom clustering algorithms to aid in early recognition and diagnosis. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Showing 39 out of 40